Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Wellcome Leap for the Opioid Crisis: Can the 5HT2A Agonist Psilocybin Improve Brain, Behavioral, and Clinical Outcomes in Opioid Use Disorder (OUD)?

NCT06786325 is registered in ClinicalTrials.gov with Anna Rose Childress, Ph.D. as lead sponsor.

NCT NCT06786325
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06786325 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Wellcome Leap for the Opioid Crisis: Can the 5HT2A Agonist Psilocybin Improve Brain, Behavioral, and Clinical Outcomes in Opioid Use Disorder (OUD)?
Lead sponsor
Anna Rose Childress, Ph.D.
Phase
Phase 2
Overall status
Recruiting
Start date
October 7, 2025
Completion date
October 31, 2027
Enrollment
36 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

opioid use disorder